MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells

Molecular and Cellular Biochemistry

Volumn 388, Issue 1-2, 2014, Pages 123-133

  Huo, Wei ^a   Jin, Ning ^a   Fan, Li ^a   Wang, Weihua ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Adenovirus; miR 122; miR 143; miR 145; Prostate carcinoma; TRAIL

Indexed keywords

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; G1 PHASE; GENETIC THERAPY; GENETIC VECTORS; HEPATOCYTES; HUMANS; LIVER; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; PROSTATE; PROSTATIC NEOPLASMS; RESPONSE ELEMENTS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSAMINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84893832902     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1904-3     Document Type: Article

References (48)

1. Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53:171-184
2. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236
3. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113 (Pubitemid 27161256)
4. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818 (Pubitemid 27366732)
5. Huang Y, Sheikh MS (2007) TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 224:284-289 (Pubitemid 47575675)
6. Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jegou B, Patard JJ, Guillaudeux T (2006) Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 66:987-995 (Pubitemid 43849596)
7. Yu R, Mandlekar S, Ruben S, Ni J, Kong AN (2000) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 60:2384-2389 (Pubitemid 30262427)
8. Chen Q, Lou W, Shen J, Ma L, Yang Z, Liu L, Luo J, Qian C (2010) Potent antitumor activity in experimental hepatocellular carcinoma by adenovirus-mediated coexpression of TRAIL and shRNA against COX-2. Clin Cancer Res 16:3696-3705
9. Griffith TS, Broghammer EL (2001) Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 4:257-266 (Pubitemid 32851290)
10. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S (2007) DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 14:976-984 (Pubitemid 350115354)
11. Jimenez JA, Li X, Zhang YP, Bae KH, Mohammadi Y, Pandya P, Kao C, Gardner TA (2010) Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Ther 17:180-191
12. Vanoosten RL, Moore JM, Ludwig AT, Griffith TS (2005) Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11:542-552 (Pubitemid 40353112)
13. Kasman L, Lu P, Voelkel-Johnson C (2007) The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther 14:327-334
14. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M (2003) Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 63:2369-2372 (Pubitemid 36605170)
15. Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D, Kassahn D, Torgler R, Mueller C, Schneider P, Brunner T (2006) TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Investig 116:2493-2499 (Pubitemid 44330148)
16. Sontheimer EJ, Carthew RW (2005) Silence from within: endogenous siRNAs and miRNAs. Cell 122:9-12 (Pubitemid 40977934)
17. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122:6-7 (Pubitemid 40977933)
18. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671-681
19. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stohr R, Hartmann A, Wullich B, Grasser F (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8:529-538
20. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, Dyrskjot L, Eltze E, Wieland W, Keck B, Ekici AB, Grasser F, Wullich B (2012) MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130:611-621
21. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH, Srougi M (2013) MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 31:796-801
22. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, Avances C, Villalba M, Culine S, Fajas L (2009) miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One 4:e7542
23. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, Li P, Zhang W, Wu H, Feng N, Wang Z, Hua L, Wang X (2011) miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350:207-213
24. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, Chen S, Lai Y, Du H, Chen G, Liu G, Tang Y, Huang S, Zou X (2011) Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6:e20341
25. Wu D, Huang P, Wang L, Zhou Y, Pan H, Qu P (2013) MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer. Mol Med Rep 8:626-630
26. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27:1788-1793 (Pubitemid 351380263)
27. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, Thibodeau SN (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69:9490-9497
28. Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A (2013) The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer 108:2573-2581
29. Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H, Hartmann A, Stoehr R, Wieland W, Grasser FA, Wullich B (2013) The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J 280:2105-2116
30. Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, Zou X, Peng X (2013) Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR145. Int J Oncol 42:1473-1481
31. Guo W, Ren D, Chen X, Tu X, Huang S, Wang M, Song L, Zou X, Peng X (2013) HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biochem 114:1606-1615
32. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, Dahiya R (2010) The functional significance of microRNA-145 in prostate cancer. Br J Cancer 103:256-264
33. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N (2011) Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 38:1093-1101
34. Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D, Fisher PB (2011) Developing an effective gene therapy for prostate cancer: new technologies with potential to translate from the laboratory into the clinic. Discov Med 11:46-56
35. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126:1166-1176
36. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, Tanaka Y, Dahiya R (2011) MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32:772-778
37. Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X (2012) miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep 28:1831-1837
38. Nana-Sinkam SP, Croce CM (2013) Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93:98-104
39. Ma L, Liu J, Shen J, Liu L, Wu J, Li W, Luo J, Chen Q, Qian C (2010) Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther 9:554-561
40. Bo Y, Guo G, Yao W (2013) MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth. J Neurooncol 112:27-37
41. Zhao Y, Li Y, Wang L, Yang H, Wang Q, Qi H, Li S, Zhou P, Liang P, Wang Q, Li X (2013) microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer. J Exp Clin Cancer Res 32:10
42. Liu J, Ma L, Li C, Zhang Z, Yang G, Zhang W (2013) Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. Mol Oncol. doi: 10.1016/j.molonc.2013.08.003
43. Jin H, Lv S, Yang J, Wang X, Hu H, Su C, Zhou C, Li J, Huang Y, Li L, Liu X, Wu M, Qian Q (2011) Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS One 6:e21307
44. Zhang Z, Zhang X, Newman K, Liu X (2012) MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Mol Cancer Ther 11:2410-2418
45. Wang B, Liu J, Ma LN, Xiao HL, Wang YZ, Li Y, Wang Z, Fan L, Lan C, Yang M, Hu L, Wei Y, Bian XW, Chen D, Wang J (2013) Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling. J Gastroenterol 48:798-808
46. Lou W, Chen Q, Ma L, Liu J, Yang Z, Shen J, Cui Y, Bian XW, Qian C (2013) Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. J Mol Med (Berl) 91:715-725
47. He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, Li L, Wu H, Liu X, Wu M, Qian Q (2011) 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Hum Gene Ther 22:283-292
48. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M (2005) Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64:854-858 (Pubitemid 40733908)